ReviewBiomolecules2025
A Review on Low-Dimensional Nanoarchitectonics for Neurochemical Sensing and Modulation in Responsive Neurological Outcomes.
Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neural Regulation of Cardiac Arrhythmias: From the Brain-Heart Axis to Emerging Precision Therapies.Research (Washington, D.C.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Low-Dimensional Nanohybrids (LDNHs) have emerged as potent multifunctional platforms for neurosensing and neuromodulation, providing elevated spatial-temporal precision, versatility, and biocompatibility. This review examines the intersection of LDNHs with artificial intelligence, brain-computer interfaces (BCIs), and closed-loop neurotechnologies, highlighting their transformative potential in personalized neuro-nano-medicine. Utilizing stimuli-responsive characteristics, optical, thermal, magnetic, and electrochemical LDNHs provide real-time feedback-controlled manipulation of brain circuits. Their pliable and adaptable structures surpass the constraints of inflexible bioelectronics, improving the neuronal interface and reducing tissue damage. We also examined their use in less invasive neurological diagnostics, targeted therapy, and adaptive intervention systems. This review delineates recent breakthroughs, integration methodologies, and fundamental mechanisms, while addressing significant challenges such as long-term biocompatibility, deep-tissue accessibility, and scalable manufacturing. A strategic plan is provided to direct future research toward clinical use. Ultimately, LDNHs signify a transformative advancement in intelligent, tailored, and closed-loop neurotechnologies, integrating materials science, neurology, and artificial intelligence to facilitate the next era of precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.